# Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib

> **NCT00471328** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 248 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Nilotinib
- **OTHER:** Best Supportive Care (BSC) +/- imatinib or sunitinib

## Key facts

- **NCT ID:** NCT00471328
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-08
- **Final completion:** 2011-06
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2012-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471328, "Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00471328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*